SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Schedules 2010 Annual Meeting of Shareholders Beijing — June 18, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi] [June 1 , 20 10 Dear Shareholder: You are cordially invited to attend the 20 10 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on July 15, 2010 , at 9 : 00 A .M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in] [SINOVAC BIOTECH LTD. ( Incorporated in Antigua and Barbuda with limited liability) ( NASDAQ Ticker: SVA) FORM OF PROXY FOR 20 10 ANNUAL SHAREHOLDERS MEETING (AND ANY ADJOURNMENT THEREOF) (Note 1) I/We, 10 (Note 2) Annual Shareholders Meeting 10 Annual Shareholders meeting of the Company to be held on July 1 5 , 20 10 at 9:00 A.M. Beijing time] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T02:58:11+00:00 June 21st, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Schedules 2010 Annual Meeting of Shareholders Beijing

[Sinovac Schedules 2010 Annual Meeting of Shareholders Beijing — June 18, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi] [June 1 , 20 10 Dear Shareholder: You are cordially invited to attend the 20 10 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on July 15, 2010 , at 9 : 00 A .M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in] [SINOVAC BIOTECH LTD. ( Incorporated in Antigua and Barbuda with limited liability) ( NASDAQ Ticker: SVA) FORM OF PROXY FOR 20 10 ANNUAL SHAREHOLDERS MEETING (AND ANY ADJOURNMENT THEREOF) (Note 1) I/We, 10 (Note 2) Annual Shareholders Meeting 10 Annual Shareholders meeting of the Company to be held on July 1 5 , 20 10 at 9:00 A.M. Beijing time] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T02:59:48+00:00 June 21st, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] CORRESP: 41st Floor, One Exchange Square 8 Connaught Place,

[41st Floor, One Exchange Square 8 Connaught Place, Central Hong Kong Tel: +852.2522.7886 Fax: +852.2522.7006 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Brussels New York June 15, 2010 Chicago Orange County Doha Paris VIA EDGAR Dubai Riyadh Frankfurt Rome Jim B. Rosenberg, Senior Assistant Chief Hamburg San Diego Don Abbott, Senior Staff Accountant]

By | 2016-03-24T03:02:26+00:00 June 15th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2010 Financial Results - Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT – — Sinovac Biotech Ltd. ( Beijing — May 13, 2010 NASDAQ: SVA), a leading China-based vaccine manufacturer , announc ed today its un audited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:06:19+00:00 May 19th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2010 Financial Results

[Sinovac Reports Unaudited First Quarter 2010 Financial Results - Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT – — Sinovac Biotech Ltd. ( Beijing — May 13, 2010 NASDAQ: SVA), a leading China-based vaccine manufacturer , announc ed today its un audited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:08:05+00:00 May 19th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[FORM 20-F (Mark One) o OR x For the fiscal year ended December 31, 2009 OR o For the transition period from to OR o Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . . SINOVAC BIOTECH LTD. N/A Antigua, West Indies (Jurisdiction] [Asset Acquisition Agreement In Relation to Guangda Pharmaceutical Party A: Beijing Xingchang High-tech Development Corporation Legal Representative: Hailing Wang Address: No. 9 Chaoqian Road, Changping District Beijing Party B: Sinovac Biotech Co., Ltd. Legal Representative: Aihua Pan Address: No. 39 Shangdi West Road, Haidian District Beijing Whereas: 1. Party A is a development enterprise located in the Changping Section of] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Beijing Sinovac Biological Technology Co., Ltd., a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 1 EX-8.1 3 a10-7773_2ex8d1.htm EX-8.1] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jinling Qin , certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Weidong Yin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.1 6 a10-7773_2ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Jinling Qin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.2 7 a10-7773_2ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 16, 2010, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By | 2016-03-24T03:10:37+00:00 April 16th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 20-F: FORM 20-F (Mark One) o OR x For

[FORM 20-F (Mark One) o OR x For the fiscal year ended December 31, 2009 OR o For the transition period from to OR o Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . . SINOVAC BIOTECH LTD. N/A Antigua, West Indies (Jurisdiction] [Asset Acquisition Agreement In Relation to Guangda Pharmaceutical Party A: Beijing Xingchang High-tech Development Corporation Legal Representative: Hailing Wang Address: No. 9 Chaoqian Road, Changping District Beijing Party B: Sinovac Biotech Co., Ltd. Legal Representative: Aihua Pan Address: No. 39 Shangdi West Road, Haidian District Beijing Whereas: 1. Party A is a development enterprise located in the Changping Section of] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Beijing Sinovac Biological Technology Co., Ltd., a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 1 EX-8.1 3 a10-7773_2ex8d1.htm EX-8.1] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jinling Qin , certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Weidong Yin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.1 6 a10-7773_2ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Jinling Qin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.2 7 a10-7773_2ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 16, 2010, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By | 2016-03-24T03:11:31+00:00 April 16th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results - Conference call scheduled Tuesday, April 6, 2010 at 9:00 a.m. EDT - - Provides full year 2010 sales guidance of $67.1 million to $72.5 million - BEIJING, April 6 /PRNewswire-Asia/ — Sinovac Biotech Ltd. ( Nasdaq: SVA), a leading China-based vaccine manufacturer, announc ed today its] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:12:45+00:00 April 7th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More
Skip to toolbar